Glioblastoma exploits this malleability by enriching the local TME with immunomodulatory factors such as transforming growth factor β (TGF-β) and interleukin-10 (IL-10), which polarize TAMs to their immunosuppressive phenotype and reduce their antigen-presenting capabilities [43,49] (Figure 1). The gene discussed is IL10; the disease is glioblastoma.